TMO - Thermo Fisher Scientific Inc.

NYSE - NYSE Delayed Price. Currency in USD
251.45
-0.77 (-0.31%)
At close: 4:01PM EST

251.45 0.00 (0.00%)
After hours: 5:14PM EST

Stock chart is not supported by your current browser
Previous Close252.22
Open250.87
Bid242.13 x 800
Ask252.22 x 800
Day's Range249.70 - 251.57
52 Week Range199.85 - 253.91
Volume807,839
Avg. Volume1,858,623
Market Cap101.228B
Beta (3Y Monthly)1.31
PE Ratio (TTM)34.73
EPS (TTM)7.24
Earnings DateApr 23, 2019 - Apr 29, 2019
Forward Dividend & Yield0.68 (0.27%)
Ex-Dividend Date2018-12-14
1y Target Est269.75
Trade prices are not sourced from all markets
  • Big Brother Billionaires Get Rich as China Watches Everyone
    Bloomberg6 hours ago

    Big Brother Billionaires Get Rich as China Watches Everyone

    When Dai started his company in 1994, roadside surveillance cameras were rare in China. The 54-year-old former academic, who now drives a luxury sedan and rewards high-performing employees with BMWs, is the latest of at least four businessmen to amass billion-dollar-plus fortunes from surveillance companies that count China’s government as a major client or investor.

  • Report: US company to stop sales of genetic tech in Xinjiang
    Associated Press16 hours ago

    Report: US company to stop sales of genetic tech in Xinjiang

    BEIJING (AP) — Thermo Fisher Scientific Inc. says it will no longer sell or service genetic sequencers in China's mostly Muslim region of Xinjiang following criticism that they were used for surveillance that enabled human rights abuses, The Wall Street Journal reported.

  • The Wall Street Journal21 hours ago

    [$$] Thermo Fisher to Stop Sales of Genetic Sequencers to China’s Xinjiang Region

    Thermo Fisher Scientific Inc. said Wednesday it will no longer be selling or servicing genetic sequencers in China’s Xinjiang region, following mounting criticism that its products were used for state surveillance of citizens there that enabled human rights abuses. It didn’t specify whether it would continue to sell these sequencers elsewhere in China. The devices were described in a December 2017 Wall Street Journal article that highlighted the ways Chinese police gather DNA samples from many citizens who aren’t criminal suspects.

  • Thermo Fisher Scientific Inc. (NYSE:TMO): Time For A Financial Health Check
    Simply Wall St.4 days ago

    Thermo Fisher Scientific Inc. (NYSE:TMO): Time For A Financial Health Check

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Thermo Fisher Scientific Inc. (NYSE:TMO), a large-capRead More...

  • Pacific Biosciences (PACB) Incurs Q4 Loss, Revenues Fall Y/Y
    Zacks9 days ago

    Pacific Biosciences (PACB) Incurs Q4 Loss, Revenues Fall Y/Y

    Pacific Biosciences' (PACB) dismal fourth-quarter 2018 results can be attributed to disappointing performance by the company's Product Revenue segment.

  • The World's Top 10 Health Care Companies (UNH, MDT)
    Investopedia13 days ago

    The World's Top 10 Health Care Companies (UNH, MDT)

    Discover the world's top 10 health care companies according to market capitalization, including a brief summary of each.

  • Markit13 days ago

    See what the IHS Markit Score report has to say about Thermo Fisher Scientific Inc.

    Thermo Fisher Scientific Inc NYSE:TMOView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is extremely low for TMO with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting TMO. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding TMO totaled $16.52 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Industrials sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Roper (ROP) Sells Scientific Imaging Businesses to Teledyne
    Zacks15 days ago

    Roper (ROP) Sells Scientific Imaging Businesses to Teledyne

    The divestment of Roper's (ROP) Scientific Imaging businesses is in sync with its inorganic growth strategy.

  • MoneyShow16 days ago

    5 Reasons to Buy Thermo Fisher

    Thermo Fisher Scientific (TMO) bills itself as "the world leader in serving science." The life-sciences titan provides a variety of equipment, supplies, and services for both the research and practical sides of the healthcare market, Richard Moroney, editor of Dow Theory Forecasts.

  • The Zacks Analyst Blog Highlights: Boeing, Thermo Fisher, Anthem, PayPal and Pfizer
    Zacks17 days ago

    The Zacks Analyst Blog Highlights: Boeing, Thermo Fisher, Anthem, PayPal and Pfizer

    The Zacks Analyst Blog Highlights: Boeing, Thermo Fisher, Anthem, PayPal and Pfizer

  • Torque and Thermo Fisher Scientific Announce Collaboration to Build State-of-the-Art Facility to Manufacture Torque's Deep-Primed T Cell Immunotherapies
    PR Newswire17 days ago

    Torque and Thermo Fisher Scientific Announce Collaboration to Build State-of-the-Art Facility to Manufacture Torque's Deep-Primed T Cell Immunotherapies

    CAMBRIDGE, Mass. and WALTHAM, Mass., Feb. 4, 2019 /PRNewswire/ -- Torque, an immuno-oncology company developing first-in-class Deep Primed™ T Cell Therapeutics to direct immune power deep within the tumor microenvironment, and Thermo Fisher Scientific Inc. (TMO), today announced a collaboration to build a dedicated Slipstream™ manufacturing facility for high-efficiency production of Torque's Deep-Primed T cell immunotherapies. Buildout of the Torque/Thermo Fisher manufacturing facility has begun, and the companies anticipate processing patient cells by the end of 2019. "Torque's cell manufacturing technology platform is critical to achieving our goal of developing and commercializing a new class of cellular immunotherapy for cancer patients with both early and advanced disease, particularly for the large population of solid tumor patients in need of new treatments," said Bart Henderson, CEO of Torque.

  • Top Analyst Reports for Boeing, Thermo Fisher & Anthem
    Zacks20 days ago

    Top Analyst Reports for Boeing, Thermo Fisher & Anthem

    Top Analyst Reports for Boeing, Thermo Fisher & Anthem

  • GlobeNewswire20 days ago

    Factors of Influence in 2019, Key Indicators and Opportunity within Rexnord, Carlisle Companies, Acorda Therapeutics, Valmont Industries, Reliance Steel & Aluminum, and Thermo Fisher Scientific — New Research Emphasizes Economic Growth

    NEW YORK, Feb. 01, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.

  • Thomson Reuters StreetEvents21 days ago

    Edited Transcript of TMO earnings conference call or presentation 30-Jan-19 1:30pm GMT

    Q4 2018 Thermo Fisher Scientific Inc Earnings Call

  • Thermo Fisher Scientific Inc (TMO) Q4 2018 Earnings Conference Call Transcript
    Motley Fool22 days ago

    Thermo Fisher Scientific Inc (TMO) Q4 2018 Earnings Conference Call Transcript

    TMO earnings call for the period ending December 31, 2018.

  • This Highly Rated Medical Giant Just Delivered 'Another Monster' Quarter
    Investor's Business Daily22 days ago

    This Highly Rated Medical Giant Just Delivered 'Another Monster' Quarter

    Thermo Fisher Scientific came in with "another monster" quarter on Wednesday — easily topping fourth-quarter expectations, one analyst noted. Thermo Fisher stock rose in midday action.

  • Thermo Fisher execs talk M&A after $1.1B pathology business sale
    American City Business Journals22 days ago

    Thermo Fisher execs talk M&A after $1.1B pathology business sale

    "Primarily we spend capital on (mergers and acquisitions). We’ve strengthened the balance sheet substantially, and the anatomical pathology sale will give us even more firepower to deploy over time," Thermo Fisher CEO Marc Casper said Wednesday.

  • Thermo Fisher (TMO) Beats on Earnings and Revenues in Q4
    Zacks22 days ago

    Thermo Fisher (TMO) Beats on Earnings and Revenues in Q4

    Thermo Fisher (TMO) gains on growth in all business segments in Q4.

  • Thermo Fisher Scientific (TMO) Tops Q4 Earnings and Revenue Estimates
    Zacks22 days ago

    Thermo Fisher Scientific (TMO) Tops Q4 Earnings and Revenue Estimates

    Thermo Fisher (TMO) delivered earnings and revenue surprises of 1.88% and 4.32%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press22 days ago

    Thermo Fisher: 4Q Earnings Snapshot

    On a per-share basis, the Waltham, Massachusetts-based company said it had net income of $2.22. Earnings, adjusted for one-time gains and costs, were $3.25 per share. The results surpassed Wall Street ...

  • Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2018 Results
    PR Newswire22 days ago

    Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2018 Results

    WALTHAM, Mass. , Jan. 30, 2019 /PRNewswire/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ...

  • Investing.com23 days ago

    Thermo Fisher Scientific Earnings, Revenue beat in Q4

    Investing.com - Thermo Fisher Scientific (NYSE:TMO) reported fourth quarter earnings that beat analysts' expectations on Wednesday and revenue that topped forecasts.

  • Benzinga23 days ago

    Thermo Fisher Scientific Q4 Earnings Preview

    Thermo Fisher Scientific (NYSE: TMO ) announces its next round of earnings this Wednesday, Jan. 30. Here's Benzinga's advanced look at Thermo Fisher Scientific's Q4 earnings report. Earnings and Revenue ...

  • Thermo Fisher (TMO) Down on Business Divestment Declaration
    Zacks23 days ago

    Thermo Fisher (TMO) Down on Business Divestment Declaration

    Thermo Fisher's (TMO) Anatomical Pathology business comes under its Specialty Diagnostics segment catering to customers at healthcare and clinical laboratories.

  • Reuters24 days ago

    Thermo Fisher to sell pathology unit for $1.14 billion

    (Reuters) - Thermo Fisher Scientific Inc, the world's largest maker of scientific instruments, will sell its anatomical pathology business for $1.14 billion in cash, the company said on Monday. The buyer ...